OXNARD, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, nutraceutical and medical foods markets, and developing cannabinoid molecules and new chemical entities (NCEs), today announces a distribution and license agreement with Long Beach, Calif-based, Redbarn Pet Products, LLC (“Redbarn”), for the development of various oral thin film veterinary products. The demand for US animal health products is more than $12 billion per year.
“This agreement is important for CURE as it marks the first distribution and licensing agreement we have executed since we received our method of use patent for animal products. We are grateful and excited to be working with such a high quality partner and look forward to a long-standing relationship with Redbarn,” said Rob Davidson, CEO of CURE Pharmaceutical. “Further, it demonstrates the versatility of our CureFilm™ technology, allowing it to easily be applied to both human and animal consumption, as well as both OTC and Rx formulation. We anticipate multiple additional deals to be announced in the short term, and look forward to sharing these milestones with our stockholders.”
As part of the agreement, CURE will formulate, develop and manufacture a variety of pet products, including multi-vitamins; flea, tick, heartworm, weight control, joint care, dental, skin health, digestive health, behavioral relief, anal gland and antifungal; hip and joint; allergies, pain and anti-nausea products to be sold over-the-counter. CURE will also provide Redbarn with products for dogs and cats specifically distributed through veterinary offices, including anti-inflammatory, pain relief, itch relief, allergies, anti-nausea, blood pressure or fluid retention, epilepsy and seizure control; heart, antibiotics and steroids. All of these products will utilize the company’s proprietary formulation and manufacturing capabilities and its patented CureFilm™ technology. “We are thrilled to be in business with CURE Pharmaceutical, as their in-house formulation, development and manufacturing capabilities provide us with a single partner that shows the same dedication to quality and purity on which we at Redbarn pride ourselves,” added Jeff Baikie, Co-CEO of Redbarn Pet Products. “We look forward to a long and fruitful relationship with CURE and are excited about the potential for the product lines we bring to market.”
About CURE Pharmaceutical Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com .
About Redbarn Pet Products, LLC: In 1996, Redbarn co-owners (and lifelong friends) Jeff Baikie and Howard Bloxam recognized the need for a wholesome dog food that was developed, produced and sold with integrity, honesty and only top quality ingredients. They developed the signature Redbarn Rolled Food, an enhanced food with over 93% digestibility. Soon, they began manufacturing premium, grass-fed bully sticks and other natural chews. In 2013, responding to customer’s demands, Jeff and Howard created the grain-free Redbarn for Cats line. Redbarn is proud to be celebrating 20 years of providing products and information to help our customers in making educated, nutritious decisions for their pets.
Forward-looking statements This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com
